Linda E Dean1,2, Gary J Macfarlane1,2, Gareth T Jones3,4. 1. From the Epidemiology Group, University of Aberdeen; Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK. 2. L.E. Dean, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.J. Macfarlane, MD (Hons), Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.T. Jones, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen. 3. From the Epidemiology Group, University of Aberdeen; Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK. gareth.jones@abdn.ac.uk. 4. L.E. Dean, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.J. Macfarlane, MD (Hons), Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen; G.T. Jones, PhD, Epidemiology Group, University of Aberdeen, and Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen. gareth.jones@abdn.ac.uk.
Abstract
OBJECTIVE: A chronic inflammatory condition manifesting in young adulthood, ankylosing spondylitis (AS) affects both physical and emotional quality of life (QOL). To inform future intervention strategies, this study aimed to (1) assess the QOL of patients with AS, and (2) identify potentially modifiable factors associated with reporting poor QOL. METHODS: The Scotland Registry for Ankylosing Spondylitis collects clinical and patient-reported data on clinically diagnosed patients with AS across Scotland. QOL is measured using the ASQoL questionnaire [range: 0 (high) to 18 (poor)]. Potentially modifiable factors associated with reporting poor QOL (score 12-18) were examined using Poisson regression models, adjusted for a variety of demographic characteristics, plus various nonmodifiable factors. Results are given as risk ratios (RR) with 95% CI. RESULTS: Data were available on 959 patients: 74% male, mean age 52 years (SD 13), median ASQoL 7.0 (interquartile range 2-12). Although many factors were univariately associated with poor QOL, 5 were identified as independent predictors: reporting moderate/severe fatigue (RR 1.60, 95% CI 1.13-2.28), poor physical function [Bath Ankylosing Spondylitis Functional Index (BASFI) ≥ 4: 3.46, 1.76-6.82], chronic widespread pain (CWP; 1.92, 1.33-2.75), high disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4: 1.52, 1.09-2.12], and poor spinal mobility [Bath Ankylosing Spondylitis Metrology Index (BASMI) ≥ 4: 1.52, 0.93-2.50]. For these factors, population-attributable risks ranged between 20% (disease activity) and 56% (physical function). CONCLUSION: We have identified 5 potentially modifiable factors independently associated with poor QOL. These findings provide evidence that in addition to traditional clinical targets (BASDAI, BASFI, and BASMI), focus on nonspecific symptoms (CWP and fatigue), perhaps with nonpharmacological therapies, may yield important improvements in QOL.
OBJECTIVE: A chronic inflammatory condition manifesting in young adulthood, ankylosing spondylitis (AS) affects both physical and emotional quality of life (QOL). To inform future intervention strategies, this study aimed to (1) assess the QOL of patients with AS, and (2) identify potentially modifiable factors associated with reporting poor QOL. METHODS: The Scotland Registry for Ankylosing Spondylitis collects clinical and patient-reported data on clinically diagnosed patients with AS across Scotland. QOL is measured using the ASQoL questionnaire [range: 0 (high) to 18 (poor)]. Potentially modifiable factors associated with reporting poor QOL (score 12-18) were examined using Poisson regression models, adjusted for a variety of demographic characteristics, plus various nonmodifiable factors. Results are given as risk ratios (RR) with 95% CI. RESULTS: Data were available on 959 patients: 74% male, mean age 52 years (SD 13), median ASQoL 7.0 (interquartile range 2-12). Although many factors were univariately associated with poor QOL, 5 were identified as independent predictors: reporting moderate/severe fatigue (RR 1.60, 95% CI 1.13-2.28), poor physical function [Bath Ankylosing Spondylitis Functional Index (BASFI) ≥ 4: 3.46, 1.76-6.82], chronic widespread pain (CWP; 1.92, 1.33-2.75), high disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4: 1.52, 1.09-2.12], and poor spinal mobility [Bath Ankylosing Spondylitis Metrology Index (BASMI) ≥ 4: 1.52, 0.93-2.50]. For these factors, population-attributable risks ranged between 20% (disease activity) and 56% (physical function). CONCLUSION: We have identified 5 potentially modifiable factors independently associated with poor QOL. These findings provide evidence that in addition to traditional clinical targets (BASDAI, BASFI, and BASMI), focus on nonspecific symptoms (CWP and fatigue), perhaps with nonpharmacological therapies, may yield important improvements in QOL.
Entities:
Keywords:
ANKYLOSING SPONDYLITIS; ASQOL; EPIDEMIOLOGY; QUALITY OF LIFE; SPONDYLOARTHRITIS
Authors: Panagiotis Athanassiou; Anastasios Kotrotsios; Ioannis Kallitsakis; Andreas Bounas; Theodoros Dimitroulas; Alexandros Garyfallos; Maria G Tektonidou; Giorgos Vosvotekas; Achilleas Livieratos; Evangelia Petrikkou; Gkikas Katsifis Journal: Qual Life Res Date: 2021-11-28 Impact factor: 4.147
Authors: Marina Magrey; Michael Bozyczko; Daniel Wolin; Margaret Mordin; Lori McLeod; Eric Davenport; Costel Chirila; Yujin Park Journal: Drugs Real World Outcomes Date: 2019-06
Authors: Maike Imkamp; Valéria Lima Passos; Annelies Boonen; Suzanne Arends; Maxime Dougados; Robert Landewé; Sofia Ramiro; Filip Van den Bosch; Desirée van der Heijde; Freke R Wink; Anneke Spoorenberg; Astrid van Tubergen Journal: RMD Open Date: 2018-11-14
Authors: Fumio Hirano; Désirée van der Heijde; Floris A van Gaalen; Robert B M Landewé; Cécile Gaujoux-Viala; Sofia Ramiro Journal: Rheumatology (Oxford) Date: 2021-01-05 Impact factor: 7.580